Seer Inc. Cl A (SEER): Price and Financial Metrics
GET POWR RATINGS... FREE!
SEER POWR Grades
- Sentiment is the dimension where SEER ranks best; there it ranks ahead of 59.13% of US stocks.
- The strongest trend for SEER is in Value, which has been heading up over the past 178 days.
- SEER ranks lowest in Quality; there it ranks in the 4th percentile.
SEER Stock Summary
- SEER's price/sales ratio is 18.47; that's higher than the P/S ratio of 94.14% of US stocks.
- SEER's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 8.25% of US stocks.
- As for revenue growth, note that SEER's revenue has grown 134.14% over the past 12 months; that beats the revenue growth of 94.77% of US companies in our set.
- Stocks that are quantitatively similar to SEER, based on their financial statements, market capitalization, and price volatility, are CWAN, IONQ, QNST, NRGV, and RKLB.
- SEER's SEC filings can be seen here. And to visit SEER INC's official web site, go to www.seer.bio.
SEER Valuation Summary
- SEER's EV/EBIT ratio is -2.8; this is 142.75% lower than that of the median Healthcare stock.
- Over the past 28 months, SEER's price/sales ratio has gone down 8709.8.
Below are key valuation metrics over time for SEER.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SEER | 2023-03-17 | 18.5 | 0.6 | -3.1 | -2.8 |
| SEER | 2023-03-16 | 19.5 | 0.7 | -3.2 | -3.0 |
| SEER | 2023-03-15 | 18.8 | 0.7 | -3.1 | -2.9 |
| SEER | 2023-03-14 | 18.6 | 0.6 | -3.1 | -2.8 |
| SEER | 2023-03-13 | 18.4 | 0.6 | -3.1 | -2.8 |
| SEER | 2023-03-10 | 17.8 | 0.6 | -3.0 | -2.7 |
SEER Price Target
For more insight on analysts targets of SEER, see our SEER price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $55.00 | Average Broker Recommendation | 1.75 (Moderate Buy) |
SEER Stock Price Chart Interactive Chart >
SEER Price/Volume Stats
| Current price | $4.05 | 52-week high | $16.53 |
| Prev. close | $4.49 | 52-week low | $3.60 |
| Day low | $4.05 | Volume | 252,449 |
| Day high | $4.61 | Avg. volume | 457,532 |
| 50-day MA | $4.73 | Dividend yield | N/A |
| 200-day MA | $7.31 | Market Cap | 258.17M |
Seer Inc. Cl A (SEER) Company Bio
Seer, Inc., a life sciences company, engages in developing nanoparticle technology solutions for researchers in the areas of proteomics information. The company develops Proteograph, an integrated solution comprising consumables, automation instrumentation, and proprietary software that performs proteomics analysis. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Latest SEER News From Around the Web
Below are the latest news stories about SEER INC that investors may wish to consider to help them evaluate SEER as an investment opportunity.
Q4 2022 Seer Inc Earnings CallQ4 2022 Seer Inc Earnings Call |
Seer, Inc. (SEER) Reports Q4 Loss, Misses Revenue EstimatesSeer, Inc. (SEER) delivered earnings and revenue surprises of 14.29% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 OutlookGrew revenue 134% and increased instruments shipped 129% year over yearREDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2022. “I am extremely proud of the Seer team and our accomplishments in our first year of broad commercial availability. The Proteograph Product Suite has been performing exc |
Companies Like Seer (NASDAQ:SEER) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Down -26.63% in 4 Weeks, Here's Why You Should You Buy the Dip in Seer, Inc. (SEER)Seer, Inc. (SEER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
SEER Price Returns
| 1-mo | -8.78% |
| 3-mo | -25.55% |
| 6-mo | -50.49% |
| 1-year | -73.90% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -30.17% |
| 2022 | -74.57% |
| 2021 | -59.37% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...